



Program

WORLD CONGRESS ON CONTROVERSIES IN
OBESITY AND DIABETES
THE FUTURE OF OBESITY
AND DIABETES 2025-2030

21-22 October 2025

InterContinental David Hotel, Tel Aviv, Israel



www.codi2025.com

All lectures will be presented in Hebrew except for the speakers from abroad | הרצאות של הכנס הינן בעברית למעט המרצים מחו"ל

Tuesday, 21 October 2025

08:00-08:50 **Registration & Welcome Refreshments**

HALL A/B

08:50-09:00 **Opening Remarks & Welcome**
Prof. Itamar Raz, Israel

Session 1: Present and Future in the Treatment of Obesity and Diabetes
Chairs: Prof. Paolo Pozzilli, Italy and Prof. Itamar Raz, Israel

09:00-09:20 **Obesity, State of the Art**
Dr. Idit Dotan, Rabin Medical Center

09:20-09:40 **Prevention – How should we manage pre-diabetes**
Prof. Naim Shehadeh, Russell Berrie Diabetes SPHERE

09:40-10:10 **Obesity Management at the Heart of Cardiovascular Health**
Prof. Jorge Plutzky, Brigham and Women's Hospital, Harvard Medical School, USA
Sponsored by Novo Nordisk

10:10-10:30 **Roundtable Discussion**

10:30-11:00 **Refreshments, Networking & Visit the Exhibition**

HALL A

11:00-13:00 **Session 2: Transforming Obesity Care: The Role of Pharmacology in New Treatment Paradigms**
Chair: Prof. Avivit Cahn, Israel
Sponsored by Novo Nordisk

11:00-11:25 **Managing Obesity – Weight Loss or Health Gain?**
Prof. Avivit Cahn, Hadassah Hebrew University Medical Center

HALL B

11:00-13:00 **Session 3: Diabetes Type 1 Debate**
Chairs: Prof. Paolo Pozzilli, Italy and Prof. Ram Weiss, Israel

11:00-11:10 **Opening **
Prof. Paolo Pozzilli, Campus Bio-Medico University of Rome, Italy & St. Bartholomew's and London School of Medicine, Queen Mary University of London, UK

11:25-11:50	Understanding Obesity's Cardiovascular Risk <i>Prof. Alon Eisen, Rabin Medical Center</i>	11:10-11:40	Treatment to Delay Type 1 Diabetes – Yes/No Yes <i>Prof. Zohar Landau, Meuhedet Health Services</i> No <i>Prof. Itamar Raz, Specialist in Internal Medicine, Diabetes and Obesity</i> Sponsored by Sanofi
11:50-12:15	New Evidence on MASH Management <i>Dr. Helena Katchman, Tel Aviv Sourasky Medical Center – Ichilov</i>	11:40-12:10	SGLT-2/GLP-1 – in Type 1 Diabetes – For / Against For <i>Prof. Ram Weiss, Rambam Medical Center</i> Against <i>Prof. David Zangen, Hadassah Medical Center</i>
12:15-12:40	Advancements in CKD <i>Dr. Nomy Levin Iaina, Barzilai University Medical Center</i>	12:10-12:30	Cure for Type 1 Diabetes  <i>Prof. Paolo Pozzilli, Campus Bio-Medico University of Rome, Italy & St. Bartholomew's and London School of Medicine, Queen Mary University of London, UK</i>
12:40-13:00	Panel Discussion & Q&A	12:30-13:00	Roundtable Discussion
13:00-13:20	Short Coffee Break, Networking & Visit the Exhibition		

13:20-15:20	Session 4: The Role of Ozempic in the Prevention and Treatment of Cardio Kidney Metabolic Syndrome Chair: Prof. Avivit Cahn, Israel Sponsored by Novo Nordisk	13:20-15:00	Session 5: Target Organs in Diabetes Chair: Prof. Itamar Raz, Israel and Prof. Haim Lotan, Israel
13:20-13:45	Understanding the CKM Syndrome: The Role of Family Physicians in the Journey of the Patient with Diabetes Prof. Avivit Cahn, Hadassah Hebrew University Medical Center	13:20-13:30	Opening Prof. Haim Lotan, Hadassah University Medical Center
13:45-14:10	Cardiovascular Complications in Patients with Type 2 Diabetes: Should Cardiovascular Considerations Dictate Choice of Medications? Prof. Avishay Grupper, Shamir Medical Center	13:30-13:50	Breakthrough in the Treatment of Kidney Failure with SGLT2i Sponsored by Boehringer Ingelheim Dr. Tali Steinmetz, Beilenson Nephrocardiac Clinic
14:10-14:35	Preventing Renal Deterioration in Patients with Diabetes Prof. Roy Eldor, Tel Aviv Sourasky Medical Center	13:50-14:10	A Decade of The SGLT2i: Revolution Insights and the Road Ahead Sponsored by Boehringer Ingelheim Dr. Ben Sadeh, Ichilov Hospital and Laniado Hospital
14:35-15:00	Overview of Diabetes and Peripheral Artery Disease (PAD) Prof. Avivit Cahn, Hadassah Hebrew University Medical Center	14:10-14:40	Cardiovascular Renal Disease in Type 1, Same Treatment -Yes/No Prof. Itamar Raz, Specialist in Internal Medicine, Diabetes and Obesity VS Prof. Haim Lotan, Hadassah University Medical Center
15:00-15:20	Open Discussion and Q&A Session	14:40-15:00	Roundtable Discussion
15:20-16:00	Lunch Break, Networking & Visit the Exhibition		
16:00	End of Day One		

Wednesday, 22 October 2025

HALL A		HALL B	
08:00-09:00	Registration & Welcome Refreshments		
09:00-09:30	The New First EASO Framework for the Pharmacological Treatment of Obesity and its Complications <i>Prof. Dror Dicker, President of the Israeli Association for Study of Obesity</i>	09:00-10:50	Session 7: Diabetes and Target Organs <i>Chairs: Prof. Edo Birati, Israel and Prof. Rifaat Safadi</i>
09:30-10:50	Session 6: Obesity as a Chronic Disease: The Past and the Future <i>Chaired by Prof. Dror Dicker, Israel</i> Sponsored by Eli Lilly	09:00-09:10	Introduction <i>Prof. Rifaat Safadi, Hadassah Hebrew University Medical Center</i>
09:30-10:00	The Conversation That Changes Everything <i>Dr. Batya Kornboim, Private Obesity Clinic Manager</i>	09:10-09:30	The Amyloid Antibody - Yes / No <i>Prof. David Tanne, Rambam Medical Center</i>
10:00-10:25	Lifestyle Matters, But Treatment Moves the Needle <i>Dr. Idit Dotan, Rabin Medical Center</i>	09:30-09:55	The Liver Cure of MASH <i>Prof. Ziv Ben Ari, Assuta Medical Center & Prof. Rifaat Safadi, Hadassah Hebrew University Medical Center</i>
10:25-10:50	The Future Is Now: What Early Obesity Treatment Could Mean <i>Dr. Gabriela Lieberman, Sheba Medical Center</i>	09:55-10:20	The Heart SGLT-2 vs GLP-1 GLP-1 <i>Prof. Edo Birati, Poria Hospital</i> SGLT-2 <i>Prof. Michal Laufer Perl, Tel Aviv Sourasky Medical Center</i>
		10:20-10:50	Roundtable Discussion
10:50-11:20	Refreshments, Networking & Visit the Exhibition		

11:20-13:00	Session 8: Early Treatment in T2D Chair: Prof. Roy Eldor, Israel Sponsored by Eli Lilly	11:20-13:00	Session 9: Target Lipids in Diabetes Prof. Ronen Durst, Israel and Dr. Idit Dotan, Israel
11:20-11:55	What If We Could Rewrite the T2D Journey from Day One? Prof. Roy Eldor, Tel Aviv Sourasky Medical Center	11:20-11:30	Opening Prof. Ronen Durst, Hadassah Medical Center
11:55-12:30	Seeing the Patient Beyond Glycaemic Metrics Prof. Avivit Cahn, Hadassah Hebrew University Medical Center	11:30-12:00	LDL Lowering for Type 1 – Like type 2 Yes Prof. Ronen Durst, Hadassah Medical Center No Dr. Noga Minsky, Sheba Medical Center
12:30-13:00	Dual Agonist Role in the Future of T2D Dr. Yoel Toledano, Meuhedet Medical Services, Maternal-Fetal Medicine Unit Rabin Medical Center, Beilinson Campus	12:00-12:25	LDL/TG Lowering Target in T2D Sponsored by Sanofi Prof. David Pereg, Meir Medical Center
		12:25-12:40	The Effect of Ozempic in Obesity Victoriya Finkel-Pekarsky, Ministry of Health
		12:40-13:00	Roundtable Discussion
13:00-13:20	Short Coffee Break, Networking & Visit the Exhibition		
13:20-14:50	Session 10: AI in Diabetes & Obesity Chairs: Dr. Gideon D. Matthews, Israel and Prof. Dror Dicker, Israel	13:20-14:50	Session 11: Diabetes Chairs: Prof. Roy Eldor, Israel and Dr. Michael Weinfass, Israel
13:20-13:40	The Role of Early Intervention in Obesity Treatment: Significance and Feasibility Sponsored by Rafa Prof. Dror Dicker, President of the Israeli Association for Study of Obesity	13:20-13:30	Introduction Prof. Roy Eldor, Tel Aviv Sourasky Medical Center

13:40-14:00	Family Medicine 4.0 – The Digital, Internet and Telephone Revolution and Today AI <i>Dr. Gideon D. Matthews, PhD, Alpha Tau Medical</i>	13:30-13:50	Time to Refocus: Where should our efforts go in combating obesity and cardio metabolic risk? 10%/20% 20% <i>Dr. Michael Weinfass, Maccabi Medical Services</i> 10% <i>Prof. Roy Eldor, Tel Aviv Sourasky Medical Center</i>	
14:00-14:20	AI, Pharma(cy) & Obesity - Opportunities and Challenges <i>Prof. Eyal Schwartzberg, Ben Gurion School of Pharmacy, Ben Gurion University, Israel. Pharmaceutical Society of Israel (PSI)</i>	13:50-14:10	Treatment of Obesity - When to Intensify Treatment - Hunger or Weight? Weight <i>Prof. Roy Eldor, Tel Aviv Sourasky Medical Center</i> Hunger <i>Dr. Idit Dotan, Rabin Medical Center</i>	
14:20-14:40	Roundtable Discussion	14:10-14:40	Roundtable Discussion	
Short Break		Short Break		
14:40-14:50	Congress Closing Remarks <i>Prof. Itamar Raz, Israel</i>			
14:50-15:30	Lunch Break, Networking & Visit the Exhibition			
15:30	End of Congress			

Industry Sponsorship

Platinum Sponsor



Sponsors



Exhibitors



בחרו באוזמפיק®



IL250ZM00050

רק אוזמפיק® מגן על הכליות, על הלב ועל החיים

של חולי הסכרת עם CKD, ומתועדף באיזון הגליקמי וההפחתה במשקל

T2D, Type 2 Diabetes; **CKD**, Chronic Kidney disease

The information presented is based on the FLOW study and is consistent with the approved label. Semaglutide 1 mg (Ozempic) is indicated for the treatment of adults with insufficiently controlled T2D as an adjunct to diet and exercise.

Kidney composite outcome included: onset of kidney failure (dialysis, transplantation, or an eGFR of <15 ml per minute per 1.73 m²), at least a 50% reduction in the eGFR from baseline, or death from kidney-related or cardiovascular causes.

Reference: Perkovic et al. N Engl J Med 2024;391:109-121.

For complete information please refer to the updated physician leaflet in the MOH website.

For information on the **approved product's indications, most common adverse events, and significant warnings**, scan the QR code:

Need additional information? contact the Marketing Authorization Holder at: www.novonordisk.co.il



המסלול לפסגה

המסע הדיגיטלי שלך עם **מאונג'רו**, בכל מקום בכל זמן.

הצטרף למהפכה בניהול המשקל וסוכרת סוג 2



התאם אישית



• מאונג'רו אינה כוללת מחטים, ולכן יש לרשום מרשם נפרד עבורן • עיינו בעלון לרופא, הכולל מידע חשוב על בטיחות
יש לתת את הדעת להיסטוריה של המטופל ולעקוב אחר אי-סבילות ותופעות לוואי

Type 2 Diabetes Mounjaro is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise • As monotherapy when metformin is considered inappropriate due to intolerance or contraindications • In addition to other medicinal products for the treatment of diabetes.

Chronic Weight Management Mounjaro is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of • $\geq 30 \text{ kg/m}^2$ (obesity) or • $\geq 27 \text{ kg/m}^2$ to $< 30 \text{ kg/m}^2$ (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes, or type 2 diabetes mellitus).

רק אוזמפיק®

מגן על הכליות, על הלב ועל החיים של חולי הסוכרת עם CKD, ומתועדף באיזון הגליקמי וההפחתה במשקל



26% הפחתה בסיכון לאירועים קרדיווסקולריים (MACE) בחולי סוכרת סוג 2 עם סיכון גבוה למחלה קרדיו וסקולרית או מחלה טרשתית קיימת (ASCVD)



24% הפחתה בסיכון להדרדרות של מחלת הכליות בהשוואה לפלצבו בחולי סוכרת סוג 2 עם מחלת כליות כרונית



עד 80% מהמטופלים מגיעים ליעדי איזון של $HbA1c < 7\%$ ועד 6.5 ק"ג הפחתה במשקל

CKD= Chronic Kidney disease. MACE = major adverse cardiovascular event: nonfatal MI, nonfatal stroke, CV death. ASCVD = Atherosclerotic Cardiovascular Disease. The information presented is based on the FLOW study and is consistent with the approved label. Semaglutide 1mg (Ozempic) is indicated for the treatment of adults with insufficiently controlled T2D as an adjunct to diet and exercise. Kidney composite outcome included: onset of kidney failure (dialysis, transplantation, or an eGFR of <15 ml per minute per 1.73 m²), at least a 50% reduction in the eGFR from baseline, or death from kidney-related or cardiovascular causes.



Reference:

1. Perkovic et al. N Engl J Med 2024;391:109-121.
2. Aroda VR et al Diabetes & Metabolism Volume 45, Issue 5, October 2019, Pages 409-418 (Sustain 1-7).
3. Lingvay I et al The Lancet Volume 7, Issue 11p834-844 November 2019 (Sustain 8).
4. Zinman B et al The Lancet Volume 7, Issue 5p356-367 May 2019 (Sustain 9).
5. Capehorn MS et al. Diabetes & Metabolism Volume 46, Issue 2, April 2020, Pages 100-109 (Sustain 10).
6. SP Marso et al. N Engl J Med. 2016;375(19):1834-1844 (SUSTAIN 6).

For complete information please refer to the **updated physician leaflet** in the MOH website.

For information on the **approved product's indications, most common adverse events, and significant warnings**, scan the QR code.

Need additional information? contact the Marketing Authorization Holder at: www.novonordisk.co.il